Last reviewed · How we verify
Conversion to extended-release tacrolimus
Conversion to extended-release tacrolimus, marketed by Massachusetts General Hospital, holds a position in the immunosuppressive drug market with a key composition patent expiring in 2028. The drug's key strength lies in its extended-release formulation, which may offer improved patient compliance and reduced dosing frequency compared to immediate-release alternatives. The primary risk is the potential for increased competition as the key patent expires in 2028, potentially leading to generic entry and market share erosion.
At a glance
| Generic name | Conversion to extended-release tacrolimus |
|---|---|
| Also known as | Envarsus XR |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (PHASE4)
- CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients (PHASE2, PHASE3)
- Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR. (EARLY_PHASE1)
- Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes (NA)
- Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial) (PHASE4)
- Envarsus XR in Lung Transplant (PHASE2)
- PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus (PHASE4)
- Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |